Every day, women in menopause notice the changes: skin that tears more easily, wounds that heal more slowly, dryness that no moisturizer seems to fix. These are not simply cosmetic concerns; they're among the skin-related physiological consequences of estrogen loss that affect quality of life in ways that often go unaddressed.
The FDA's November 2025 decision to remove the boxed warning from menopausal hormone therapy products marks a turning point after more than two decades of clinical caution. While women’s health practitioners have long prescribed hormone therapy, this regulatory shift offers an opportunity for dermatologists to revisit the often overlooked benefits of hormone therapy: its effects on aging skin in addition to vulvovaginal health.
The Biology of Estrogen and Skin
Estrogen receptors are present throughout skin tissue, and their decline after menopause triggers measurable physiological changes. Skin collagen content decreases at a rate of approximately 1%-2% per year in the early postmenopausal period, skin thickness diminishes, barrier function weakens, and moisture retention falters. These changes translate to increased skin fragility, impaired wound healing, and visible aging that can significantly impact quality of life. Click here to read more.
